Allogene Therapeutics Business Summary

Allogene Therapeutics, Inc. (ALLO) is a clinical-stage biotechnology company that generates revenue primarily through strategic collaboration agreements, licensing fees, and milestone payments from partners such as Pfizer and Servier, rather than commercial product sales. The company’s business model is centered on the development of "off-the-shelf" allogeneic chimeric antigen receptor (AlloCAR T) therapies, which utilize healthy donor T-cells to provide on-demand treatment at scale. Its primary business segments are categorized by therapeutic indication: hematologic malignancies (led by the pivotal Phase 2 ALPHA3 trial for cema-cel in Large B-Cell Lymphoma), solid tumors (targeting renal cell carcinoma with ALLO-316), and a growing portfolio in autoimmune diseases (ALLO-329). Allogene competes directly with other cell therapy pioneers such as Fate Therapeutics, CRISPR Therapeutics, and Caribou Biosciences, maintaining a market-leading position as the first to advance an allogeneic CAR T candidate into a registration-enabling pivotal study. The company was founded by a high-pedigree team of cell therapy veterans, most notably Executive Chairman Arie Belldegrun, M.D., and President and CEO David Chang, M.D., Ph.D., both of whom were instrumental in the success of Kite Pharma and the approval of the first autologous CAR T therapy, Yescarta. The current leadership team includes Benjamin M. Beneski as Senior Vice President and Chief Technical Officer, Geoffrey Parker as Executive Vice President and Chief Financial Officer, and Zachary J. Roberts, M.D., Ph.D., as EVP of Research & Development and Chief Medical Officer. Allogene is backed by a robust roster of institutional investors and strategic stakeholders, including Pfizer Inc., TPG Capital, and BlackRock. The Board of Directors features prominent industry figures such as Lead Independent Director Dr. Franz Humer and TPG co-founder David Bonderman, providing the company with deep operational and financial governance as it nears potential commercialization.